MX2016007902A - Composiciones y metodos para el tratamiento del glaucoma. - Google Patents

Composiciones y metodos para el tratamiento del glaucoma.

Info

Publication number
MX2016007902A
MX2016007902A MX2016007902A MX2016007902A MX2016007902A MX 2016007902 A MX2016007902 A MX 2016007902A MX 2016007902 A MX2016007902 A MX 2016007902A MX 2016007902 A MX2016007902 A MX 2016007902A MX 2016007902 A MX2016007902 A MX 2016007902A
Authority
MX
Mexico
Prior art keywords
methods
compositions
glaucoma
treatment
dexmedetomidine
Prior art date
Application number
MX2016007902A
Other languages
English (en)
Inventor
Horn Gerald
Original Assignee
Gnt Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/132,780 external-priority patent/US20140107173A1/en
Application filed by Gnt Llc filed Critical Gnt Llc
Publication of MX2016007902A publication Critical patent/MX2016007902A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona composiciones del agonista del receptor adrenérgico a-2 y métodos para tratar el glaucoma y otras condiciones intraoculares. El agonista a-2 preferido utilizado en las composiciones y métodos de la invención es la dexmedetomidina.
MX2016007902A 2013-12-18 2014-02-11 Composiciones y metodos para el tratamiento del glaucoma. MX2016007902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/132,780 US20140107173A1 (en) 2011-02-03 2013-12-18 Compositions and Methods for Treatment of Glaucoma
PCT/US2014/015797 WO2015094392A1 (en) 2013-12-18 2014-02-11 Compositions and methods for treatment of glaucoma

Publications (1)

Publication Number Publication Date
MX2016007902A true MX2016007902A (es) 2016-10-28

Family

ID=53403464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007902A MX2016007902A (es) 2013-12-18 2014-02-11 Composiciones y metodos para el tratamiento del glaucoma.

Country Status (7)

Country Link
EP (1) EP3082427A4 (es)
JP (1) JP2017501224A (es)
CN (1) CN106455567A (es)
BR (1) BR112016014404A2 (es)
CA (1) CA2934453A1 (es)
MX (1) MX2016007902A (es)
WO (1) WO2015094392A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108883102A (zh) * 2016-03-17 2018-11-23 远视眼治疗有限责任公司 用于治疗远视眼的组合物和方法
US20210251970A1 (en) 2018-10-10 2021-08-19 Presbyopia Therapies Inc Compositions and methods for storage stable ophthalmic drugs
CN111481506B (zh) * 2019-01-25 2023-01-24 江苏恒瑞医药股份有限公司 一种包含经鼻给药的右美托咪定组合物的药物制品
CN116474219A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
CN112107544A (zh) * 2019-06-28 2020-12-22 四川普锐特药业有限公司 右美托咪定鼻喷剂、其制备方法及应用
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN115137699B (zh) * 2021-03-29 2024-05-03 四川普锐特药业有限公司 一种增效防腐的右美托咪定鼻喷剂
US12180206B2 (en) 2021-11-17 2024-12-31 Lenz Therapeutics Operations, Inc. Aceclidine derivatives, compositions thereof and methods of use thereof
US12414942B1 (en) 2024-03-15 2025-09-16 Lenz Therapeutics Operations, Inc. Compositions, methods, and systems for treating presbyopia

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290964A (en) * 1994-07-08 1996-01-17 Arto Olavi Urtti Transdermal drug delivery system
CA2534484A1 (en) * 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
US20110152271A1 (en) * 2009-12-17 2011-06-23 Gerald Horn Compositions and methods for ophthalmic delivery of nasal decongestants
US20110189174A1 (en) * 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
WO2011127151A2 (en) * 2010-04-07 2011-10-13 Allergan, Inc. Combinations of preservatives for ophthalmic compositions
US20130172357A1 (en) * 2011-02-03 2013-07-04 Eye Therapies Llc Compositions and Methods for Treatment of Glaucoma
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
US20140107173A1 (en) * 2011-02-03 2014-04-17 Gnt, Llc Compositions and Methods for Treatment of Glaucoma
CN103796652A (zh) * 2011-07-14 2014-05-14 阿勒根公司 羟甲唑啉的凝胶组合物及使用方法
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2863760A1 (en) * 2012-02-02 2013-08-08 Alpha Synergy Development, Inc. Compositions and methods for treatment of glaucoma
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
BR112016014404A2 (pt) 2017-08-08
CN106455567A (zh) 2017-02-22
CA2934453A1 (en) 2015-06-25
EP3082427A1 (en) 2016-10-26
WO2015094392A1 (en) 2015-06-25
JP2017501224A (ja) 2017-01-12
EP3082427A4 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
MX2016007902A (es) Composiciones y metodos para el tratamiento del glaucoma.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12020500255A1 (en) Use of nk-1 receptor antagonist serlopitant in pruritus
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2020002216A (es) Metodos y composiciones para detectar y tratar endometriosis.
MX2016015862A (es) Compuestos inhibidores de la cinasa de union a tank.
JO3564B1 (ar) ببتيدات وتركيبات لعلاج ضرر المفاصل
MX364657B (es) Compuestos de quinolina selectivamente sustituida.
MX2016009312A (es) Composiciones y metodos para el tratamiento de la neovascularizacion y/o fuga intraocular.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2017002374A (es) Composiciones y metodos para tratar trastornos de la vision.
MX377593B (es) Composiciones para usar en el tratamiento de cáncer renal.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX2020000367A (es) Inhibidores de rad51.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
EA201491894A1 (ru) Способы лечения непереносимости лактозы
TW201612160A (en) Compounds as CRTH2 antagonist and uses thereof
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MA39824A (fr) Composés azole amido-substitués
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
MX2022016251A (es) Compuestos antagonistas receptores de somatostatina y metodos para utilizarlos.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions